Demonstration by synovial fluid analysis of the efficacy in horses of an investigational drug (L-1016)

A glycosaminoglycan polysulfate ester, L-1016, was administered intra-articularly over a period of six-weeks to selected horses with joint disorders which demonstrated by synovial fluid analysis lesions and/or degeneration of the articular cartilage and impairment of synovial membrane function. Over the course of treatment, significant changes in synovial fluid viscosity and protein were observed. In general, these laboratory data were reflected directly in clinical observations. Response to the treatment was characterized by decreases in outward signs of swelling, increases in flexion and lessening of lameness.